Barclays lifts target for Iovance Biotherapeutics stock to USD 18.00

Published on 10/15/2026 at 20:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts average USD 13.20 across 13 firms on October 14, 2026. Iovance Biotherapeutics stock costs EUR 12.86 on October 15, 2026 at 10:20 p.m. CEST.

Analyst views and reporting date

Barclays lifted its Iovance target to USD 18.00 on October 13, 2026.
MarketBeat reported a USD 13.20 average target from 13 firms on October 14, 2026.
Iovance Biotherapeutics stock costs EUR 12.86 at Lang & Schwarz on October 15, 2026 at 10:20 p.m. CEST.
Iovance is expected to report third-quarter results on November 5, 2026.

IOVA, US4622601007, Illustration mit AI erstellt.

Barclays lifted its price target for Iovance Biotherapeutics to USD 18.00 from USD 15.00 on October 13, 2026, according to Markets Insider. The upgrade gives the analyst view a clear role in the stock's current valuation debate.

Iovance Biotherapeutics stock was trading at EUR 12.86 at Lang & Schwarz on October 15, 2026 at 10:20 p.m. CEST. The euro quotation is an after-hours indication for investors in Germany.

Analyst targets remain divided

MarketBeat reported on October 14, 2026 that 13 firms had a Moderate Buy consensus, with nine Buy ratings, three Holds and one Sell. Their average 12-month target was USD 13.20, below the reported USD 14.50 share price cited in that article.

The spread between Barclays at USD 18.00 and the USD 13.20 average shows why target selection matters. The Barclays target is USD 3.68 above the latest Nasdaq quote of USD 14.32, while the consensus figure sits USD 1.12 below it.

Revenue growth meets a loss

Iovance reported USD 99.31 million of revenue for the second quarter of 2026, up 65.70 percent from the year-earlier quarter, while adjusted earnings per share were a loss of USD 0.11, according to MarketBeat. The company had raised its 2026 revenue outlook to USD 410 million to USD 420 million on September 29, 2026, according to Iovance Biotherapeutics.

Price range and next date

The latest Nasdaq quote was USD 14.32 on October 15, 2026 at 2:30 p.m. EDT, up 0.81 percent from USD 14.21. The 52-week range was USD 1.76 to USD 15.30, leaving the share USD 0.98 below its yearly high.

Iovance had a market capitalization of USD 6.5 billion and a negative price-to-earnings ratio of 19.62 as of October 15, 2026. The Wall Street Journal listed November 5, 2026 as the next earnings date.

Comparison with peers

IOVA: plus 0.81 percent, P/E minus 19.62, market capitalization USD 6.5 billion. Adaptimmune: plus 13.33 percent, P/E minus 0.11, market capitalization USD 9.0 million. Sangamo Therapeutics: plus 2.57 percent, market capitalization USD 59.5 million.

What the next report could clarify

The November report will put the USD 410 million to USD 420 million outlook alongside another quarterly revenue figure. For investors, the central tension is visible in the numbers: revenue reached USD 99.31 million in the second quarter, but the company still reported a loss.

The further course of trading is shown by the continuously updated real-time quote of Iovance Biotherapeutics stock.